FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2085-2098 November 16, 2006 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Remuzzi, G. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined.

Methods In this open-label trial, we studied 1432 patients with chronic kidney disease, 715 of whom were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 13.5 g per deciliter and 717 of whom were assigned to receive a dose targeted to achieve a level of 11.3 g per deciliter. The median study duration was 16 months. The primary end point was a composite of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), and stroke.

Results A total of 222 composite events occurred: 125 events in the high-hemoglobin group, as compared with 97 events in the low-hemoglobin group (hazard ratio, 1.34; 95% confidence interval, 1.03 to 1.74; P=0.03). There were 65 deaths (29.3%), 101 hospitalizations for congestive heart failure (45.5%), 25 myocardial infarctions (11.3%), and 23 strokes (10.4%). Seven patients (3.2%) were hospitalized for congestive heart failure and myocardial infarction combined, and one patient (0.5%) died after having a stroke. Improvements in the quality of life were similar in the two groups. More patients in the high-hemoglobin group had at least one serious adverse event.

Conclusions The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 [ClinicalTrials.gov] .)

Source Information

From the Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston (A.K.S.); the Renal Division, Duke University Medical Center (L.S., D.R.), Duke Clinical Research Institute (L.S., S.S.), and the Department of Biostatistics and Bioinformatics, Duke University (H.B.) — all in Durham, NC; Ortho Biotech Clinical Affairs, Bridgewater, NJ (K.L.T., M.W.); and the Department of Medicine, University College Galway, Galway, Ireland (D.R.).

Address reprint requests to Dr. Singh at the Renal Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at asingh{at}partners.org.

Full Text of this Article

This article has been cited by other articles:

• Metzger, N. L., Francis, K. E., Voils, S. A. (2008). A Comparative Review of Erythropoiesis Stimulating Agents. Journal of Pharmacy Practice 21: 424-430 [Abstract]  
• Saltiel, M. (2008). The Erythropoietic Receptors Agonists: FDA Warnings, Changing Guidelines, and Other Responses to Negative Data. Journal of Pharmacy Practice 21: 402-404 [Abstract]  
• Silverberg, D. S., Wexler, D., Iaina, A., Schwartz, D. (2008). The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure. Journal of Pharmacy Practice 21: 420-423 [Abstract]  
• Smith, L. E. H. (2008). Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture. IOVS 49: 5177-5182 [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Vaziri, N. D., Zhou, X. J. (2008). Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 0: gfn601v1-gfn601 [Full Text]  
• Akizawa, T., Pisoni, R. L., Akiba, T., Saito, A., Fukuhara, S., Asano, Y., Hasegawa, T., Port, F. K., Kurokawa, K. (2008). Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 23: 3643-3653 [Abstract] [Full Text]  
• Canaud, B., Mingardi, G., Braun, J., Aljama, P., Kerr, P. G., Locatelli, F., Villa, G., Van Vlem, B., McMahon, A. W., Kerloeguen, C., Beyer, U., on behalf of the STRIATA Study Investigators, (2008). Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23: 3654-3661 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2008). Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. CJASN 3: 1669-1675 [Abstract] [Full Text]  
• Summers, S., Holdsworth, S., Sharples, E. (2008). The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 23: 3053-3055 [Full Text]  
• Groenveld, H. F., Januzzi, J. L., Damman, K., van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J., van der Meer, P. (2008). Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis. J Am Coll Cardiol 52: 818-827 [Abstract] [Full Text]  
• Chonchol, M., Lippi, G., Montagnana, M., Muggeo, M., Targher, G. (2008). Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant 23: 2879-2883 [Abstract] [Full Text]  
• Chan, K. E., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., Moran, J. (2008). Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 23: 2948-2956 [Abstract] [Full Text]  
• Courneya, K. S., Jones, L. W., Peddle, C. J., Sellar, C. M., Reiman, T., Joy, A. A., Chua, N., Tkachuk, L., Mackey, J. R. (2008). Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial. The Oncologist 13: 1012-1020 [Abstract] [Full Text]  
• Anand, I. S. (2008). Anemia and Chronic Heart Failure: Implications and Treatment Options. J Am Coll Cardiol 52: 501-511 [Abstract] [Full Text]  
• Zarychanski, R. MD, Houston, D. S. MD PhD (2008). Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?. CMAJ 179: 333-337 [Full Text]  
• Dong, X., de Leon, C. M., Artz, A., Tang, Y., Shah, R., Evans, D. (2008). A Population-Based Study of Hemoglobin, Race, and Mortality in Elderly Persons. J. Gerontol. A Biol. Sci. Med. Sci. 63: 873-878 [Abstract] [Full Text]  
• Schlieper, G., Hristov, M., Brandenburg, V., Kruger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N., Gladziwa, U., Ketteler, M., Weber, C., Floege, J. (2008). Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrol Dial Transplant 23: 2611-2618 [Abstract] [Full Text]  
• Swinkels, D. W., Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23: 2450-2453 [Full Text]  
• Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., Pereira, B. J. G. (2008). Ferumoxytol for Treating Iron Deficiency Anemia in CKD. J. Am. Soc. Nephrol. 19: 1599-1605 [Abstract] [Full Text]  
• Wolf, M. (2008). Active Vitamin D and Survival. J. Am. Soc. Nephrol. 19: 1442-1443 [Full Text]  
• Maekawa, K., Shoji, T., Emoto, M., Okuno, S., Yamakawa, T., Ishimura, E., Inaba, M., Nishizawa, Y. (2008). Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant 23: 2329-2336 [Abstract] [Full Text]  
• Chhabra, D., Grafals, M., Skaro, A. I., Parker, M., Gallon, L. (2008). Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection. CJASN 3: 1168-1174 [Abstract] [Full Text]  
• Brookhart, M. A., Schneeweiss, S., Avorn, J., Bradbury, B. D., Rothman, K. J., Fischer, M., Mehta, J., Winkelmayer, W. C. (2008). The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. J. Am. Soc. Nephrol. 19: 1389-1395 [Abstract] [Full Text]  
• Murray, N., Klasa, R. (2008). Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-Stimulating Agent Guidelines. JCO 26: 3096-3097 [Full Text]  
• May, K. A., Khuri, F. R. (2008). Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion. Cancer Res. 68: 4013-4017 [Abstract] [Full Text]  
• Tong, Z., Yang, Z., Patel, S., Chen, H., Gibbs, D., Yang, X., Hau, V. S., Kaminoh, Y., Harmon, J., Pearson, E., Buehler, J., Chen, Y., Yu, B., Tinkham, N. H., Zabriskie, N. A., Zeng, J., Luo, L., Sun, J. K., Prakash, M., Hamam, R. N., Tonna, S., Constantine, R., Ronquillo, C. C., Sadda, S., Avery, R. L., Brand, J. M., London, N., Anduze, A. L., King, G. L., Bernstein, P. S., Watkins, S., Genetics of Diabetes and Diabetic Complication Stu, , Jorde, L. B., Li, D. Y., Aiello, L. P., Pollak, M. R., Zhang, K. (2008). Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl. Acad. Sci. USA 105: 6998-7003 [Abstract] [Full Text]  
• DEMIRJIAN, S. G., NURKO, S. (2008). Anemia of chronic kidney disease: When normalcy becomes undesirable. Cleveland Clinic Journal of Medicine 75: 353-356 [Abstract] [Full Text]  
• Ishani, A., Solid, C. A., Weinhandl, E. D., Gilbertson, D. T., Foley, R. N., Collins, A. J. (2008). Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 23: 1682-1689 [Abstract] [Full Text]  
• Kitamura, H., Isaka, Y., Takabatake, Y., Imamura, R., Suzuki, C., Takahara, S., Imai, E. (2008). Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 23: 1521-1528 [Abstract] [Full Text]  
• Desai, A., Zhao, Y., Warren, J. S. (2008). Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant 23: 1513-1520 [Abstract] [Full Text]  
• Auerbach, M. (2008). Should Intravenous Iron Be the Standard of Care in Oncology?. JCO 26: 1579-1581 [Full Text]  
• Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., Kaelin, W. G. Jr (2008). Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111: 3236-3244 [Abstract] [Full Text]  
• Furumatsu, Y., Nagasawa, Y., Hamano, T., Iwatani, H., Iio, K., Shoji, T., Ito, T., Tsubakihara, Y., Imai, E. (2008). Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant 23: 984-990 [Abstract] [Full Text]  
• Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., Bhasin, S. (2008). Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men. J. Clin. Endocrinol. Metab. 93: 914-919 [Abstract] [Full Text]  
• Moranne, O., Watier, L., Rossert, J., Stengel, B., The GN-Progress Study Group, (2008). Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM 101: 215-224 [Abstract] [Full Text]  
• Watnick, S., Stooksbury, M., Winter, R., Riscoe, M., Cohen, D. M. (2008). White Thrombus Formation in Blood Tubing Lines in a Chronic Hemodialysis Unit. CJASN 3: 382-386 [Abstract] [Full Text]  
• Stenvinkel, P., Carrero, J. J., Axelsson, J., Lindholm, B., Heimburger, O., Massy, Z. (2008). Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?. CJASN 3: 505-521 [Abstract] [Full Text]  
• Ronco, C., Kellum, J. A., Bellomo, R., House, A. A. (2008). Potential Interventions in Sepsis-Related Acute Kidney Injury. CJASN 3: 531-544 [Abstract] [Full Text]  
• Macdougall, I. C., Walker, R., Provenzano, R., de Alvaro, F., Locay, H. R., Nader, P. C., Locatelli, F., Dougherty, F. C., Beyer, U., on behalf of the ARCTOS study investigators, (2008). C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial. CJASN 3: 337-347 [Abstract] [Full Text]  
• Winkelmayer, W. C., Chandraker, A. (2008). Pottransplantation Anemia: Management and Rationale. CJASN 3: S49-S55 [Abstract] [Full Text]  
• Bennett, C. L., Silver, S. M., Djulbegovic, B., Samaras, A. T., Blau, C. A., Gleason, K. J., Barnato, S. E., Elverman, K. M., Courtney, D. M., McKoy, J. M., Edwards, B. J., Tigue, C. C., Raisch, D. W., Yarnold, P. R., Dorr, D. A., Kuzel, T. M., Tallman, M. S., Trifilio, S. M., West, D. P., Lai, S. Y., Henke, M. (2008). Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA 299: 914-924 [Abstract] [Full Text]  
• Kazory, A., Ross, E. A. (2008). Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective. Circulation 117: 975-983 [Abstract] [Full Text]  
• Tang, W.H. W., Tong, W., Jain, A., Francis, G. S., Harris, C. M., Young, J. B. (2008). Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.. J Am Coll Cardiol 51: 569-576 [Abstract] [Full Text]  
• Levy, W. C. (2008). Anemia in heart failure: marker or mediator of adverse prognosis?. J Am Coll Cardiol 51: 577-578 [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., Schumock, G. T. (2008). Projecting future drug expenditures--2008. Am J Health Syst Pharm 65: 234-253 [Abstract] [Full Text]  
• Annear, N.M.P., Banerjee, D., Joseph, J., Harries, T.H., Rahman, S., Eastwood, J.B. (2008). Prevalence of chronic kidney disease stages 3-5 among acute medical admissions: another opportunity for screening. QJM 101: 91-97 [Abstract] [Full Text]  
• Kapoian, T., O'Mara, N. B., Singh, A. K., Moran, J., Rizkala, A. R., Geronemus, R., Kopelman, R. C., Dahl, N. V., Coyne, D. W. (2008). Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin. J. Am. Soc. Nephrol. 19: 372-379 [Abstract] [Full Text]  
• Ghali, J. K., Anand, I. S., Abraham, W. T., Fonarow, G. C., Greenberg, B., Krum, H., Massie, B. M., Wasserman, S. M., Trotman, M.-L., Sun, Y., Knusel, B., Armstrong, P., on behalf of the Study of Anemia in Heart Failure, (2008). Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation 117: 526-535 [Abstract] [Full Text]  
• Besarab, A., Goodkin, D. A., Nissenson, A. R. (2008). The Normal Hematocrit Study -- Follow-up. NEJM 358: 433-434 [Full Text]  
• Covic, A., Gusbeth-Tatomir, P., Goldsmith, D. (2008). Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. Nephrol Dial Transplant 23: 56-61 [Full Text]  
• O'Mara, N. B. (2008). Anemia in Patients With Chronic Kidney Disease. Diabetes Spectr. 21: 12-19 [Abstract] [Full Text]  
• Singh, A. K. (2008). Anemia of Chronic Kidney Disease. CJASN 3: 3-6 [Full Text]  
• Agarwal, R., Davis, J. L., Smith, L. (2008). Serum Albumin Is Strongly Associated with Erythropoietin Sensitivity in Hemodialysis Patients. CJASN 3: 98-104 [Abstract] [Full Text]  
• Townsend, R. R. (2008). Stroke in Chronic Kidney Disease: Prevention and Management. CJASN 3: S11-S16 [Abstract] [Full Text]  
• Tonelli, M. (2007). Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun. ANN INTERN MED 147: 880-881 [Full Text]  
• Weiner, D. E., Miskulin, D. C., Seefeld, K., Ladik, V., Zager, P. G., Singh, A. K., Johnson, H. K., Meyer, K. B. (2007). Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels. J. Am. Soc. Nephrol. 18: 3184-3191 [Abstract] [Full Text]  
• Yang, W., Israni, R. K., Brunelli, S. M., Joffe, M. M., Fishbane, S., Feldman, H. I. (2007). Hemoglobin Variability and Mortality in ESRD. J. Am. Soc. Nephrol. 18: 3164-3170 [Abstract] [Full Text]  
• DeLoughery, T. G. (2007). Update in Hematology. ANN INTERN MED 147: 717-724 [Full Text]  
• Fishbane, S., Besarab, A. (2007). Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets. CJASN 2: 1274-1282 [Abstract] [Full Text]  
• Maddux, F. W, Shetty, S., del Aguila, M. A, Nelson, M. A, Murray, B. M (2007). Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease. The Annals of Pharmacotherapy 41: 1761-1769 [Abstract] [Full Text]  
• Toblli, J. E., Lombrana, A., Duarte, P., Di Gennaro, F. (2007). Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. J Am Coll Cardiol 50: 1657-1665 [Abstract] [Full Text]  
• Francis, G. S., Kanderian, A. (2007). Anemia and Heart Failure: A New Pathway?. J Am Coll Cardiol 50: 1666-1667 [Full Text]  
• Joss, N., Patel, R., Paterson, K., Simpson, K., Perry, C., Stirling, C. (2007). Anaemia is common and predicts mortality in diabetic nephropathy. QJM 100: 641-647 [Abstract] [Full Text]  
• (2007). Erythropoietin Safety Concerns. Obstet Gynecol 110: 919-921 [Full Text]  
• Tanaka, Y., Joki, N., Hase, H. (2007). History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. Nephrol Dial Transplant 22: 2917-2923 [Abstract] [Full Text]  
• Blake, P. G. (2007). Randomized controlled trials in PD. Nephrol Dial Transplant 22: 2746-2748 [Full Text]  
• Foley, R. N., Collins, A. J. (2007). End-Stage Renal Disease in the United States: An Update from the United States Renal Data System. J. Am. Soc. Nephrol. 18: 2644-2648 [Abstract] [Full Text]  
• Corwin, H. L. MD (2007). Erythropoietin use in critically ill patients: forest and trees. CMAJ 177: 747-749 [Full Text]  
• Corwin, H. L., Gettinger, A., Fabian, T. C., May, A., Pearl, R. G., Heard, S., An, R., Bowers, P. J., Burton, P., Klausner, M. A., Corwin, M. J., the EPO Critical Care Trials Group, (2007). Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. NEJM 357: 965-976 [Abstract] [Full Text]  
• Murphy, N. F., McDonald, K. (2007). Treatment of anaemia in chronic heart failure optimal approach still unclear. Eur Heart J 28: 2185-2187 [Full Text]  
• De Nicola, L., Conte, G., Chiodini, P., Cianciaruso, B., Pota, A., Bellizzi, V., Tirino, G., Avino, D., Catapano, F., Minutolo, R. (2007). Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease. CJASN 2: 938-946 [Abstract] [Full Text]  
• Husemann, W., Fobker, M., Pohlen, M., Bruch, C., Hausberg, M., Breithardt, G., Reinecke, H. (2007). Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions. Nephrol Dial Transplant 22: 2563-2570 [Abstract] [Full Text]  
• Glynn, L. G., Reddan, D., Newell, J., Hinde, J., Buckley, B., Murphy, A. W. (2007). Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 22: 2586-2594 [Abstract] [Full Text]  
• Schwenger, V., Morath, C., Zeier, M. (2007). Use of Erythropoietin after solid organ transplantation. Nephrol Dial Transplant 22: viii47-viii49 [Abstract] [Full Text]  
• Regidor, D. L., Kalantar-Zadeh, K., Kovesdy, C. P. (2007). Epoetin Dosing and Dialysis Facility Ownership. JAMA 298: 862-862 [Full Text]